South America Gastroparesis Market
SAM region consists of Brazil, Argentina, and Rest of SAM. Brazil is expected to have the major market share in this region. Also, it is projected to grow with highest growth rate. Increasing prevalence of gastroparesis in Brazil is the major cause of the country to witness rapid growth for the market. In addition, the emerging biotech and medical device sector poses opportunities for the gastroparesis market to grow. Some of the prominent countries contributing to the growth of gastroparesis market include Chile, Colombia, Peru, and Bolivia. A significant population suffers from diabetes in these countries. Moreover, presence of well-established manufacturing companies in the regions will further drive the market growth. In addition, implementation of strategic partnerships and collaborations by global market players in the region are estimated to promote the awareness of gastroparesis in the market, which will eventually drive the market growth during the forecast period.
SAM is facing significantly challenging situations due to COVID 19 pandemic. However, the recent pandemic is causing turbulence to the economies of the SAM. A sudden drop in demand for gastroparesis, diabetes, and treatments and production due to labor shortage are some of the major impacts observed in the region. In Central America countries, there is a surge in demand for normal consumer health drugs such as anti-emetic. Some countries across SAM are limiting the sales/purchase of non-prescription drugs in response to COVID-19 to maintain supply and counteract stockpiling/panic buying. The approach differs widely across the region: countries such as Brazil and Argentina have introduced strict limits, while others, such as the Peru and other SAM countries, have not ordered official restrictions.
Strategic insights for the South America Gastroparesis provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.
| Report Attribute | Details |
|---|---|
| Market size in 2020 | US$ 320.85 Million |
| Market Size by 2027 | US$ 407.30 Million |
| Global CAGR (2020 - 2027) | 3.5% |
| Historical Data | 2018-2019 |
| Forecast period | 2021-2027 |
| Segments Covered |
By Type
|
| Regions and Countries Covered | South and Central America
|
| Market leaders and key company profiles |
The geographic scope of the South America Gastroparesis refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.
The gastroparesis market in SAM is expected to grow from US$ 320.85 million in 2020 to US$ 407.30 million by 2027; it is estimated to grow at a CAGR of 3.5% from 2020 to 2027. Advanced computational technologies such as artificial intelligence (AI) and biomedical engineering hold potential to offer promising solutions for the treatment of gastroparesis. The efficacy of gastric electrical stimulation in improving gastric emptying and reducing symptoms severity in patients with diabetes gastroparesis has already been proven. Moreover, several devices have been awarded with the FDA approval for the treatment of this condition. In February 2015, Medtronic received FDA approval for its Enterra gastric neurostimulator device, which is already available in the market for the treatment of gastroparesis. The device won a regulatory approval for its use in the prevention of nausea and vomiting associated with the idiopathic and diabetic gastroparesis. The growing emphasis on the research pertaining to the gastric electrical stimulation therapy is anticipated to encourage new technology developments in the gastroparesis market, eventually allowing the market players to come up with better alternatives for the existing gastroparesis treatment modalities in the coming years.
The SAM gastroparesis market is segmented on the basis of type, drug class, distribution channel, and country. The SAM gastroparesis market, by type, is segmented into idiopathic, diabetic, post-surgical, and others. The idiopathic segment held the largest share of the market in 2019. The SAM gastroparesis market, by drug class type, is segmented into prokinetic agents, botulinum toxin injection, and antiemetic agents. The prokinetic agents segment held the largest share of the market in 2019. Based on distribution channel, the SAM gastroparesis market is segmented into retail pharmacies, hospital pharmacies, and others. The hospital pharmacies segment held the largest share of the market in 2019. Based on country, the SAM gastroparesis market is segmented into Brazil, Argentina, and rest of SAM. Brazil held the largest market share in 2019.
A few major primary and secondary sources referred to for preparing this report on the gastroparesis market in SAM are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Allergan Plc; Bausch Health Companies Inc. (Salix Pharmaceuticals, Ltd.); Ipca Laboratories Ltd.; Johnson and Johnson Services, Inc.; Pfizer Inc.; and TEVA PHARMACEUTICAL INDUSTRIES LTD.
The South America Gastroparesis Market is valued at US$ 320.85 Million in 2020, it is projected to reach US$ 407.30 Million by 2027.
As per our report South America Gastroparesis Market, the market size is valued at US$ 320.85 Million in 2020, projecting it to reach US$ 407.30 Million by 2027. This translates to a CAGR of approximately 3.5% during the forecast period.
The South America Gastroparesis Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the South America Gastroparesis Market report:
The South America Gastroparesis Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The South America Gastroparesis Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the South America Gastroparesis Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For South America Gastroparesis Market
